Quality of life (QoL) outcomes with futibatinib treatment in FOENIX-CCA2-A phase II study in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions/rearrangements

被引：0

作者：

Valle, J. W. ^{[1
]}

Hollebecque, A. ^{[2
]}

Furuse, J. ^{[3
]}

Goyal, L. ^{[4
]}

Meric-Bernstam, F. ^{[5
]}

Morlock, R. ^{[6
]}

He, Y. ^{[7
]}

Benhadji, K. ^{[8
]}

Bridgewater, J. ^{[9
]}

机构：

[1] Univ Manchester, Div Canc Sci, Christie NHS Fdn Trust, Manchester, Lancs, England

[2] Gustave Roussy, DITEP Drug Dev Dept, Villejuif, France

[3] Kyorin Univ, Dept Med Oncol, Sch Med, Tokyo, Japan

[4] Massachusetts Gen Hosp, Dept Med Hematol Oncol, Boston, MA 02114 USA

[5] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA

[6] YourCareChoice, Sci Collaborator, Ann Arbor, AL USA

[7] Taiho Oncol, Biostat, Princeton, NJ USA

[8] Taiho Oncol Inc, Clin Dev Dept, Princeton, NJ USA

[9] UCL, Dept Med Oncol, Canc Inst, London, England

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

58P

引用

页码：S263 / S264

页数：2

共 38 条

[21] Expansion part of phase I study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression
Morizane, Chigusa
Ueno, Makoto
Ioka, Tatsuya
Tajika, Masahiro
Ikeda, Masafumi
Yamaguchi, Kensei
Hara, Hiroki
Yabusaki, Hiroshi
Miyamoto, Atsushi
Iwasa, Satoru
Muto, Manabu
Takashima, Tsutomu
Minashi, Keiko
Komatsu, Yoshito
Nishina, Tomohiro
Nakajima, Takako Eguchi
Sahara, Takatoshi
Funasaka, Setsuo
Yashiro, Masakazu
Furuse, Junji
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[22] Efficacy and safety of futibatinib in patients with locally advanced/metastatic triple-negative breast cancer harboring FGFR2 gene amplification: final results from the phase 2, open-label FOENIX-MBC2 study
Giordano, Antonio
Unni, Nisha
Damodaran, Senthil
Rugo, Hope
Crook, Timothy
Bachelot, Thomas
Piacentini, Federico
Parra, Hector Soto
Krop, Ian
Shimura, Masashi
Tomlinson, Gareth
Gil, Maciej
Turner, Nicholas
Andre, Fabrice
CANCER RESEARCH, 2024, 84 (09)
[23] Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
Harding, J.
Perez, C.
Kato, S.
Sharma, M.
Garmezy, B.
Quah, C.
Tam, B.
Severson, P.
ANNALS OF ONCOLOGY, 2023, 34 : S63 - S64
[24] A phase II telemedicine study of pemigatinib in adult patients with unresectable or metastatic pancreas cancer with FGFR2 gene fusions or other FGFR genetic alterations.
Risch, Zachary
Wing, Michele
Reeser, Julie
Stein, Leah
Dao, Thuy
Smith, Amy
Samorodnitsky, Eric
Paruchuri, Anoosha
Pan, Xueliang Jeff
Roychowdhury, Sameek
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS717 - TPS717
[25] \FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements
Bekaii-Saab, Tanios S.
Valle, Juan W.
Van Cutsem, Eric
Rimassa, Lorenza
Furuse, Junji
Ioka, Tatsuya
Melisi, Davide
Macarulla, Teresa
Bridgewater, John A.
Wasan, Harpreet Singh
Borad, Mitesh J.
Lihou, Christine F.
Zhen, Huiling
Feliz, Luis
Asatiani, Ekatherine
Jiang, Ping
Vogel, Arndt
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[26] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
Harding, James J.
Perez, Cesar Augusto
Kato, Shumei
Sharma, Manish
Garmezy, Benjamin
Quah, Cheng Seok
Tam, Betty
Severson, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS637 - TPS637
[27] Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
Javle, Milind M.
Roychowdhury, Sameek
Kelley, Robin Kate
Sadeghi, Saeed
Macarulla, Teresa
Waldschmidt, Dirk Thomas
Goyal, Lipika
Borbath, Ivan
El-Khoueiry, Anthony B.
Yong, Wei-Peng
Philip, Philip Agop
Bitzer, Michael
Tanasanvimon, Suebpong
Li Ai
Pande, Amit
Shepherd, Stacie Peacock
Moran, Susan
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[28] Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
Javle, M.
Kelley, R. K.
Roychowdhury, S.
Weiss, K. H.
Abou-Alfa, G. K.
Macarulla, T.
Sadeghi, S.
Waldschmidt, D.
Zhu, A. X.
Goyal, L.
Borad, M.
Yong, W. P.
Borbath, I.
El-Khoueiry, A.
Philip, P.
Moran, S.
Ye, Y.
Ising, M.
Lewis, N.
Bekaii-Saab, T.
ANNALS OF ONCOLOGY, 2018, 29 : 720 - 720
[29] Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Javle, Milind
Roychowdhury, Sameek
Kelley, Robin Kate
Sadeghi, Saeed
Macarulla, Teresa
Weiss, Karl Heinz
Waldschmidt, Dirk-Thomas
Goyal, Lipika
Borbath, Ivan
El-Khoueiry, Anthony
Borad, Mitesh J.
Yong, Wei Peng
Philip, Philip A.
Bitzer, Michael
Tanasanvimon, Surbpong
Li, Ai
Pande, Amit
Soifer, Harris S.
Shepherd, Stacie Peacock
Moran, Susan
Zhu, Andrew X.
Bekaii-Saab, Tanios S.
Abou-Alfa, Ghassan K.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (10): : 803 - 815
[30] Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
Abou-Alfa, G. K.
Borbath, I.
Clarke, S. J.
Hitre, E.
Louvet, C.
Macarulla, T.
Oh, D-Y.
Spratlin, J. L.
Valle, J. W.
Weiss, K. H.
Berman, C.
Howland, M.
Ye, Y.
Cho, T.
Moran, S.
Javle, M. M.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 →